BR112014014558A2 - composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica - Google Patents
composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílicaInfo
- Publication number
- BR112014014558A2 BR112014014558A2 BR112014014558A BR112014014558A BR112014014558A2 BR 112014014558 A2 BR112014014558 A2 BR 112014014558A2 BR 112014014558 A BR112014014558 A BR 112014014558A BR 112014014558 A BR112014014558 A BR 112014014558A BR 112014014558 A2 BR112014014558 A2 BR 112014014558A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- treatment
- pharmaceutical composition
- proton pump
- pump inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576640P | 2011-12-16 | 2011-12-16 | |
| PCT/GB2012/000904 WO2013088109A1 (en) | 2011-12-16 | 2012-12-14 | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014558A2 true BR112014014558A2 (pt) | 2017-06-13 |
| BR112014014558A8 BR112014014558A8 (pt) | 2017-07-04 |
Family
ID=47470031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014558A BR112014014558A8 (pt) | 2011-12-16 | 2012-12-14 | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140328861A1 (pt) |
| EP (1) | EP2790696A1 (pt) |
| JP (1) | JP2015500326A (pt) |
| KR (1) | KR20140113667A (pt) |
| CN (1) | CN104114169A (pt) |
| AU (1) | AU2012351342A1 (pt) |
| BR (1) | BR112014014558A8 (pt) |
| CA (1) | CA2859284A1 (pt) |
| EA (1) | EA026456B1 (pt) |
| IL (1) | IL233131A0 (pt) |
| MX (1) | MX2014007239A (pt) |
| SG (1) | SG11201402796SA (pt) |
| UA (1) | UA112667C2 (pt) |
| WO (1) | WO2013088109A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| PT3470432T (pt) | 2012-08-21 | 2021-12-14 | Regeneron Pharma | Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| US10059771B2 (en) | 2013-06-21 | 2018-08-28 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| EP3402572B1 (en) * | 2016-01-13 | 2022-03-16 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| RU2756270C2 (ru) * | 2016-07-21 | 2021-09-29 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Производное индола, используемое в качестве ингибитора CRTH2 |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CN111526920A (zh) | 2017-10-30 | 2020-08-11 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂来治疗或预防哮喘的方法 |
| CN107954995B (zh) * | 2017-11-30 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 具有crth2抑制剂活性的吲哚衍生物 |
| CN107987072B (zh) * | 2017-11-30 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚类化合物 |
| CN107987066B (zh) * | 2017-11-30 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚衍生物 |
| CN107936004B (zh) * | 2017-11-30 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的吲哚类衍生物 |
| US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
| MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| WO2022020464A1 (en) * | 2020-07-21 | 2022-01-27 | Ellodi Pharmaceuticals, L.P. | Modified release rapidly disintegrating compositions of proton pump inhibitors |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| AU2003231513A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Pgd2 receptor antagonist |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| AU2003269327A1 (en) | 2002-10-21 | 2004-05-04 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
| US7321001B2 (en) | 2002-12-20 | 2008-01-22 | Amgen Inc. | Asthma and allergic inflammation modulators |
| SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| PT1471057E (pt) | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| WO2005007094A2 (en) | 2003-07-09 | 2005-01-27 | Tularik Inc. | Asthma and allergic inflammation modulators |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| SI1718649T1 (sl) | 2004-01-31 | 2009-10-31 | Actimis Pharmaceuticals Inc | Derivati imidazo 1,2-c pirimidinilocetne kisline |
| NZ550365A (en) | 2004-03-11 | 2010-09-30 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| ES2345662T3 (es) | 2004-03-11 | 2010-09-29 | Actelion Pharmaceuticals Ltd. | Derivados de acido indol-1-il-acetico. |
| MXPA06011540A (es) | 2004-04-07 | 2007-01-26 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
| US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
| EP1758579A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| EA200602288A1 (ru) | 2004-05-29 | 2007-10-26 | 7ТиЭм ФАРМА А/С | Замещённые тиазолуксусные кислоты в качестве лигандов crth2 |
| US20090105218A1 (en) | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| EA200700712A1 (ru) | 2004-09-21 | 2008-02-28 | Эсерсис, Инк. | Производные индолуксусной кислоты, способ получения таких производных (варианты), фармацевтическая композиция, набор на их основе, способ ингибирования связывания эндогенных лигандов и способ лечения заболеваний и расстройств, восприимчивых к ингибированию связывания эндогенных лигандов с рецептором crth-2 |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| BRPI0608553A2 (pt) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| ES2369714T3 (es) | 2005-04-21 | 2011-12-05 | Merck Serono Sa | Pirazina sulfonamidas 2,3 sustituidas como inhibidores de crth2. |
| GB0510585D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| RU2478639C2 (ru) | 2005-05-24 | 2013-04-10 | Лаборатуар Сероно С.А. | Трициклические спиро-производные в качестве модуляторов crth2 |
| GB0510584D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| EP1747800B1 (en) * | 2005-07-29 | 2009-03-18 | Rottapharm S.p.A. | Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders |
| US7696222B2 (en) | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
| EP1931632A4 (en) | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
| GB0518494D0 (en) | 2005-09-09 | 2005-10-19 | Argenta Discovery Ltd | Thiazole compounds |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| AU2006296397B2 (en) | 2005-09-30 | 2011-12-15 | Gb001, Inc. | Quinolines and their therapeutic use |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| JP2009514935A (ja) | 2005-11-05 | 2009-04-09 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| WO2007062678A1 (en) | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
| GB0524427D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Use of receptor ligands in threapy |
| WO2007062677A1 (en) | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| GB0524428D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| TW200732296A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Novel compounds |
| CN102558021A (zh) | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| GB0611781D0 (en) | 2006-06-14 | 2006-07-26 | Argenta Discovery Ltd | 2-Oxo-2H-Chromene Compounds |
| RU2458918C2 (ru) | 2006-07-22 | 2012-08-20 | Оксаген Лимитед | Соединения, обладающие антагонистической активностью по отношению к crth2 |
| US8183289B2 (en) | 2006-08-21 | 2012-05-22 | Array Biopharma Inc. | 4-substituted phenoxyphenylacetic acid derivatives |
| JP2010513429A (ja) | 2006-12-21 | 2010-04-30 | アージェンタ ディスカバリー リミテッド | Ｃｒｔｈ２アンタゴニスト |
| GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| EA200970875A1 (ru) | 2007-03-21 | 2010-04-30 | Арджента Орал Терапьютикс Лимитед | Производные индолизинуксусной кислоты в качестве антагонистов crth2 |
| WO2008119917A1 (en) | 2007-03-29 | 2008-10-09 | Argenta Discovery Limited | Quinoline derivatives as crth2 receptor ligands |
| UA101326C2 (en) | 2007-06-21 | 2013-03-25 | Актимис Фармасьютикалз, Инк. | Amine salts of crth2 antagonist |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| CA2707785C (en) * | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| AU2008343924B2 (en) | 2007-12-19 | 2013-01-17 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
| EP2250161B1 (en) * | 2008-01-18 | 2013-10-16 | Atopix Therapeutics Limited | Compounds having crth2 antagonist activity |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
| JP2011526281A (ja) * | 2008-06-24 | 2011-10-06 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト |
| US20110312945A1 (en) * | 2008-10-01 | 2011-12-22 | James Jia | Crth2 modulators |
| WO2010042652A2 (en) * | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| JP2012072061A (ja) * | 2009-01-29 | 2012-04-12 | Eisai R & D Management Co Ltd | 新規組成物 |
| IN2012DN00359A (pt) * | 2009-07-20 | 2015-05-22 | Vetegen Llc | |
| KR20120047273A (ko) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| CN102548573B (zh) * | 2009-08-17 | 2016-03-16 | 宾州研究基金会 | Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 |
| CA2782085A1 (en) | 2010-01-06 | 2011-07-14 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
-
2012
- 2012-12-14 EA EA201491008A patent/EA026456B1/ru unknown
- 2012-12-14 MX MX2014007239A patent/MX2014007239A/es unknown
- 2012-12-14 WO PCT/GB2012/000904 patent/WO2013088109A1/en active Application Filing
- 2012-12-14 CN CN201280066423.2A patent/CN104114169A/zh active Pending
- 2012-12-14 UA UAA201407393A patent/UA112667C2/uk unknown
- 2012-12-14 JP JP2014546622A patent/JP2015500326A/ja active Pending
- 2012-12-14 BR BR112014014558A patent/BR112014014558A8/pt not_active Application Discontinuation
- 2012-12-14 SG SG11201402796SA patent/SG11201402796SA/en unknown
- 2012-12-14 KR KR1020147018762A patent/KR20140113667A/ko not_active Application Discontinuation
- 2012-12-14 CA CA2859284A patent/CA2859284A1/en not_active Abandoned
- 2012-12-14 AU AU2012351342A patent/AU2012351342A1/en not_active Abandoned
- 2012-12-14 US US14/365,306 patent/US20140328861A1/en not_active Abandoned
- 2012-12-14 EP EP12808859.8A patent/EP2790696A1/en not_active Withdrawn
-
2014
- 2014-06-15 IL IL233131A patent/IL233131A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014007239A (es) | 2014-08-08 |
| EP2790696A1 (en) | 2014-10-22 |
| BR112014014558A8 (pt) | 2017-07-04 |
| CA2859284A1 (en) | 2013-06-20 |
| NZ626990A (en) | 2016-01-29 |
| WO2013088109A1 (en) | 2013-06-20 |
| AU2012351342A1 (en) | 2014-07-24 |
| KR20140113667A (ko) | 2014-09-24 |
| JP2015500326A (ja) | 2015-01-05 |
| CN104114169A (zh) | 2014-10-22 |
| EA201491008A1 (ru) | 2015-02-27 |
| IL233131A0 (en) | 2014-07-31 |
| SG11201402796SA (en) | 2014-06-27 |
| UA112667C2 (uk) | 2016-10-10 |
| US20140328861A1 (en) | 2014-11-06 |
| EA026456B1 (ru) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014558A2 (pt) | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica | |
| SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BR112013033940A2 (pt) | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer | |
| CO6801774A2 (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| CL2013003281A1 (es) | Compuesto n-(2-{2-dimetilaminoetil-metilamino}-4-metoxi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida y sus sales; composición farmacéutica que los comprende; uso en el tratamiento del cáncer | |
| CO6801796A2 (es) | Composiciones de tratamiento de pozo de liberación retardada para uso en fluídos de tratamiento de pozo | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112013028959A2 (pt) | composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| CO6920293A2 (es) | Compuestos antibaterianos y método para su uso | |
| BR112014009471A2 (pt) | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014010739A2 (pt) | agentes terapêuticos e uso dos mesmos | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014029642A2 (pt) | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |